tiprankstipranks
Trending News
More News >

Elekta AB’s 2024/25 Annual Report: Advancing Cancer Care

Story Highlights
Elekta AB’s 2024/25 Annual Report: Advancing Cancer Care

Don’t Miss TipRanks’ Half-Year Sale

Elekta AB ( ($SE:EKTA.B) ) has provided an announcement.

Elekta AB’s annual report for 2024/25 highlights its commitment to advancing cancer care through innovation and collaboration. The report emphasizes the company’s dedication to setting new standards in treatment, reflecting its strategic milestones and sustainability efforts. This announcement underscores Elekta’s role in the healthcare sector, aiming to make a significant impact on cancer treatment and patient lives.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

More about Elekta AB

Elekta AB operates in the healthcare industry, focusing on providing advanced medical solutions for cancer treatment. The company is known for its innovative technologies and services aimed at improving patient care and outcomes in oncology.

Average Trading Volume: 1,444,854

Current Market Cap: SEK19.1B

See more data about EKTA.B stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1